INVOKANA ® (canagliflozin) Significantly Improved Renal Outcomes and Demonstrated Potential Renal Protective Effects in Patients with Type 2 Diabetes Who Have or Are at Risk for Cardiovascular Disease
Late-breaking renal data from the integrated CANVAS Program presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting (Source: Johnson and Johnson)
Source: Johnson and Johnson - November 3, 2017 Category: Pharmaceuticals Source Type: news
CANVAS: Straight Talk Needed on Amputation Risk CANVAS: Straight Talk Needed on Amputation Risk
Can a meta-analysis of two different studies or data from observational studies overcome the clinical concern about the clear-cut amputation risk with canagliflozin seen in the CANVAS trial?Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news
Janssen submits sNDA to FDA for Invokana to reduce risk of MACE
Janssen Research and Development has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events (MACE). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - October 4, 2017 Category: Pharmaceuticals Source Type: news
Janssen Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for INVOKANA ® (canagliflozin) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) Based on Landmark CANVAS Program
Filing includes data on the combined risk reduction of cardiovascular death, myocardial infarction and stroke in patients with type 2 diabetes (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 2, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Mundipharma Medical Company, Cooper Pharmal Sarl, Merck
Mundipharma Medical Company will exclusively distribute INVOKANA (canagliflozin) and VOKANAMET (canagliflozin and metformin) in the European Economic Area (EEA) and Switzerland, under an agreement signed with drug developer and manufacturer Janssen P … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
Janssen and Mundipharma sign distribution deal for type 2 diabetes treatments
Janssen Pharmaceutica has entered an exclusive distribution agreement with Mundipharma Medical Company for Invokana (canagliflozin) and Vokanamet (a fixed-dose combination therapy of canagliflozin and metformin) to treat patients with type 2 diabetes … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 4, 2017 Category: Pharmaceuticals Source Type: news
Some Physicians Switch Patients Off Invokana after FDA Warning
(MedPage Today) -- Doubled risk of amputations appears to be affecting usage (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 2, 2017 Category: Cardiology Source Type: news
Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D Positive Cardiac Biomarker Changes Seen With Canagliflozin in T2D
Canagliflozin suppressed the increase in NT-proBNP and high-sensitivity troponin in older patients with type 2 diabetes, which may help shed some light on the beneficial CV effect of SGLT2 inhibitors.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 8, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
FDA Reports Further Support for Canagliflozin-Amputation Link FDA Reports Further Support for Canagliflozin-Amputation Link
The data are still insufficient to change prescribing recommendations, but they do suggest caution in prescribing canagliflozin for people at increased amputation risk.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
CANVAS Proves CV Safety, Metabolic Value of Canagliflozin CANVAS Proves CV Safety, Metabolic Value of Canagliflozin
British diabetes expert Clifford Bailey offers his take on the CANVAS dataMedscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 30, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news
CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Some see the newly revealed cardiovascular benefits as rendering canagliflozin essentially"interchangeable" with empagliflozin, while others view the amputation signal as a deal breaker.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Janssen reports positive results from CANVAS programme of canagliflozin
Janssen-Cilag International has reported positive results from the CANVAS programme of INVOKANA (canagliflozin) in combination with standard-of-care to address a combined risk of cardiovascular (CV) death, non-fatal myocardial infarction (MI) and non … (Source: Drug Development Technology)
Source: Drug Development Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news
ADA: Canagliflozin Cuts Heart Risk in T2D (CME/CE)
(MedPage Today) -- But CANVAS program reveals risk of amputation, fracture (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - June 13, 2017 Category: Consumer Health News Source Type: news
New diabetes pill costs just £1.30 a day
Canagliflozin, a pill taken once a day before breakfast, is designed to lower blood sugar levels and keep weight down. Experts last night said the study heralds a 'new era' in treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - June 13, 2017 Category: Consumer Health News Source Type: news
INVOKANA ® (canagliflozin) Significantly Reduces the Combined Risk of Cardiovascular Death, Myocardial Infarction and Stroke in the CANVAS Program
Study results published in the New England Journal of Medicine and featured in a special symposium at the American Diabetes Association 77th Scientific Sessions (Source: Johnson and Johnson)
Source: Johnson and Johnson - June 13, 2017 Category: Pharmaceuticals Source Type: news
